Hims & Hers Health stock may be undervalued following FDA scrutiny of peptide safety, according to an analysis by Simply Wall St. The company has delivered a roughly 344.6% return over three years, yet its price-to-sales ratio of about 3.7 times sits below a tailored fair P/S estimate of approximately 9.5 times, suggesting a sizeable discount. However, broader valuation checks are weak, with the stock passing only two of six checks, and the analysis notes that the current price around US$38 may reflect an appropriate cushion for regulatory and execution risk. The community is split, with a bull case seeing 78% undervaluation and a bear case arguing 43% overvaluation.
Hims Hers Health IncAnalyst valuation suggests stock may be undervalued, but also notes weak checks and split bull/bear cases.